Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | MIF | P14174 | 1/20 | 0.33 |
| ▸ | UCHL3 | P15374 | 2/20 | 0.33 |
| ▸ | UCHL1 | P09936 | 2/20 | 0.33 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5160353 | 0.80 | MAPT (0.55) | MAPTALDH1A1KMT2AHTTMIF | |
| SCHEMBL13804924 | 0.79 | MAPT (0.36) | MAPTMEN1ALDH1A1HPGDALOX12 | |
| SCHEMBL5161352 | 0.79 | ALOX5 (0.39) | MAPTHTTMIFUCHL3UCHL1 | |
| SCHEMBL5162991 | 0.79 | MAPT (0.38) | MAPTHTTMIFERBB2 | |
| SCHEMBL13804685 | 0.77 | MAPT (0.33) | MAPTMEN1ALDH1A1HPGDALOX12 | |
| SCHEMBL5160864 | 0.76 | MAPT (0.36) | MAPTALDH1A1HTTMIFUCHL3 | |
| SCHEMBL13804921 | 0.75 | PLK1 (0.60) | MAPTMEN1ALDH1A1HPGDKMT2A | |
| SCHEMBL2051065 | 0.74 | UCHL3 (0.32) | UCHL3UCHL1 | |
| SCHEMBL13804682 | 0.72 | MAPT (0.37) | MAPTALDH1A1HTT | |
| SCHEMBL5160510 | 0.71 | MAPT (0.38) | MAPTMEN1ALDH1A1HPGDALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1399114-B1 | AGENT CONTAINING QUINONIMINE DERIVATIVES AND USED TO COLOUR KERATIN FIBRES, AND ASSOCIATED METHOD | WELLA AG (DE) | 2007-03-28 | — | — | EP | claimed |
| US-7056349-B2 | Agent containing quinonimine derivatives and used to color keratin fibres, and associated method | WELLA AG (DE) | 2006-06-06 | — | — | US | claimed |
| EP-1399114-A1 | AGENT CONTAINING QUINONIMINE DERIVATIVES AND USED TO COLOUR KERATIN FIBRES, AND ASSOCIATED METHOD | Wella Aktiengesellschaft (DE) | 2004-03-24 | — | — | EP | claimed |
| US-20030182736-A1 | Agent containing quinonimine derivatives and used to colour keratin fibres, and associated method | HFC PRESTIGE INTERNATIONAL HOLDING SWITZERLAND S.A.R.L (CH) | 2003-10-02 | — | — | US | claimed |
| WO-2002102336-A1 | AGENT CONTAINING QUINONIMINE DERIVATIVES AND USED TO COLOUR KERATIN FIBRES, AND ASSOCIATED METHOD | WELLA AKTIENGESELLSCHAFT (DE) | 2002-12-27 | — | — | WO | claimed |
| EP-1399114-B1 | AGENT CONTAINING QUINONIMINE DERIVATIVES AND USED TO COLOUR KERATIN FIBRES, AND ASSOCIATED METHOD | WELLA AG (DE) | 2007-03-28 | — | — | EP | disclosed |
| US-7056349-B2 | Agent containing quinonimine derivatives and used to color keratin fibres, and associated method | WELLA AG (DE) | 2006-06-06 | — | — | US | disclosed |
| EP-1399114-A1 | AGENT CONTAINING QUINONIMINE DERIVATIVES AND USED TO COLOUR KERATIN FIBRES, AND ASSOCIATED METHOD | Wella Aktiengesellschaft (DE) | 2004-03-24 | — | — | EP | disclosed |
| US-20030182736-A1 | Agent containing quinonimine derivatives and used to colour keratin fibres, and associated method | HFC PRESTIGE INTERNATIONAL HOLDING SWITZERLAND S.A.R.L (CH) | 2003-10-02 | — | — | US | disclosed |
| WO-2002102336-A1 | AGENT CONTAINING QUINONIMINE DERIVATIVES AND USED TO COLOUR KERATIN FIBRES, AND ASSOCIATED METHOD | WELLA AKTIENGESELLSCHAFT (DE) | 2002-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030182736-A1 | Agent containing quinonimine derivatives and used to colour keratin fibres, and associated method | KRT18, MKI67, F12 | MAPT 661/4885MEN1 2048/4885ALDH1A1 380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.